Last reviewed · How we verify
NCT03260231: Lymphoseed
Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma
NA trial testing Milled seed mix in Non-hodgkin Lymphoma in 40 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | University of Belgrade |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 12 May 2017 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Serbia |
Drugs / interventions tested
- Milled seed mix
Conditions studied
- Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →
Sponsor
University of Belgrade
Who can join
Adults 20 to 70, any sex, with Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recent literature data suggest beneficial effects of dietary fats in patients with cancers, in particular polyunsaturated fatty acids (PUFAs). Milled mix of flax, sesame and pumpkin seeds provides a high amount of PUFAs and a desirable n-6/n-3 PUFAs ratio.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x
Verify or expand the search:
- PubMed search for NCT03260231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
- NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
- NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
Other University of Belgrade trials
Trials by the same sponsor.
- NCT07414433 — Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · not yet recruiting
- NCT07337759 — Fetus Programming and Long Active Outcomes, Interaction Between Mother, Placenta and Fetus in Perinatal and Methabolic D · completed
- NCT06885983 — Healing After Augmentation of Alveolar Ridge Using Collagen Membrane · NA · enrolling by invitation
- NCT07378709 — Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · recruiting
- NCT06349382 — CArbohydrate Loading in Aortic Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03260231 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Belgrade
- Last refreshed: 20 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03260231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing